Clinical Trial Update: A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing the Vielight Neuro RX Gamma device for post-COVID-19 cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Vielight Neuro RX Gamma

Snippet

Sponsor: Vielight Inc. | Conditions: Post COVID-19 Cognitive Impairment | Phase 1 | Status: COMPLETED